Structure based drug designing utilizes the information of the three-dimensional structure of the biological target to predict with what affinity and selectivity, the candidate drugs will bind to the target exploiting the interactive graphics and therefore the intuition of a medicinal chemist. This technique additionally uses the construct of homology modeling of the target if just in case the experimental structure of the target is not available. Structure-based computational methods continue to enhance progress in the discovery and refinement of therapeutic agents. many such methods and their applications are delineated . These embrace molecular visualisation and molecular modeling, docking, fragment methods, 3-D database techniques, and free-energy perturbation. the sector of structure-based drug design is a apace growing space in which many successes have occurred in recent years. The explosion of genomic, proteomic, and structural information has provided many new targets and opportunities for future drug lead discovery. A prerequisite for this new approach is an understanding of the principles of molecular recognition in protein-ligand complexes. If the three-dimensional structure of a given protein is known, this information can be directly exploited for the retrieval and design of latest ligands. Structure-based ligand design is an unvarying approach. first of all, it requires the crystal structure or a model derived from the crystal structure of a closely related homolog of the target protein, preferentially complexed with a ligand. This complex unravels the binding mode and conformation of a ligand underneath investigation and indicates the essential aspects decisive its binding affinity. it is then wont to generate new ideas about ways that of improving an existing ligand or of developing new various bonding skeletons.
Last date updated on June, 2014